type here...

CATEGORIES

Discover Drugs

LATEST

123Page 3 of 3

TRENDING

EDITORS CHOICE

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Medika Life -
ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Phexxi; Have You Heard About This New Hormone-Free Contraceptive?

Dr Jeff Livingston -
She is sick of using birth control, but now is not the right time to get pregnant. The “pull and pray” method is too...

Real-World Repercussions of Mislabeling Treatments as Vaccines

Robert Turner, Founding Editor -
Vaccinate, inoculate and immunize are three words that describe the "jab" people get to guard them against serious infectious illnesses. Harmonious - yes - but each offers a different consumer expectation.

Is Silmitasertib the Covid-19 Treatment Breakthrough We’ve Been Waiting for?

Medika Life -
Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories